Survey on the use of REXULTI for managing aggressive behavior in Alzheimer's patients
REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)
This study is testing if REXULTI can help manage aggressive behavior in people with Alzheimer's disease by looking at how well it works and its safety in everyday settings.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 15 Years and up |
| Sex | All |
| Sponsor | Otsuka Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Osaka, Osaka) |
| Trial ID | NCT06875986 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the safety and efficacy of REXULTI (brexpiprazole) in patients diagnosed with Alzheimer's disease who exhibit excessive motor activity or aggressive behavior due to mood changes. The study will collect data from daily clinical settings to assess how well the medication performs in real-world scenarios. By monitoring patient responses and side effects, the study seeks to provide valuable insights into the drug's effectiveness for managing symptoms associated with Alzheimer's.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with Alzheimer's disease who display excessive motor activity or aggressive behavior.
Not a fit: Patients who do not have a diagnosis of Alzheimer's disease or do not exhibit aggressive behaviors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the management of aggressive behaviors in Alzheimer's patients, enhancing their quality of life.
How similar studies have performed: While this approach is observational, similar studies evaluating the efficacy of medications like REXULTI in managing behavioral symptoms in dementia have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with Alzheimer's disease Exclusion Criteria: \-
Where this trial is running
Osaka, Osaka
- Pharmacovigilance Department — Osaka, Osaka, Japan (Recruiting)
Study contacts
- Study coordinator: Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd
- Email: komaniwa.satoshi@otsuka.jp
- Phone: +81-6-6943-7722
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.